-
Something wrong with this record ?
Current status of sentinel lymph node mapping in the management of cervical cancer
R. Lukas, R. Helena, HM. Jiri, H. Martin, S. Petr,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
NT13166
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
ProQuest Central
from 2001-06-01 to 2014-09-30
Health & Medicine (ProQuest)
from 2001-06-01 to 2014-09-30
Public Health Database (ProQuest)
from 2001-06-01 to 2014-09-30
- MeSH
- Sentinel Lymph Node Biopsy methods MeSH
- Time Factors MeSH
- Humans MeSH
- Lymph Node Excision MeSH
- Lymphatic Metastasis MeSH
- Uterine Cervical Neoplasms pathology therapy MeSH
- Predictive Value of Tests MeSH
- Prognosis MeSH
- Sensitivity and Specificity MeSH
- Technetium diagnostic use MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
The status of regional lymph nodes is the most important prognostic factor in early cervical cancer patients. Pelvic lymph node dissections are routinely performed as a part of standard surgical treatment. Systematic pelvic lymphadenectomy is associated with short- and long-term morbidities. This review discusses single components of the sentinel lymph node mapping (SLNM) technique and results of the detection of sentinel lymph nodes. SLNM biopsy performed by an experienced team for small volume tumors (<2 cm) has high specific side detection rate, excellent negative-predictive value and high sensitivity. Uncommon lymphatic drainage has been reported in 15% of cervical cancer patients. There is sufficient data now to suggest that SLNM with 99mTc plus blue dye in the hands of a surgeon with extensive experience should prove to be an important part of individualized cervical cancer surgery and increase the safety of less radical or fertility-sparing surgery.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14050899
- 003
- CZ-PrNML
- 005
- 20181105140459.0
- 007
- ta
- 008
- 140401s2013 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1586/14737140.2013.811147 $2 doi
- 035 __
- $a (PubMed)23875664
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Rob, Lukáš, $d 1958- $7 xx0017807
- 245 10
- $a Current status of sentinel lymph node mapping in the management of cervical cancer / $c R. Lukas, R. Helena, HM. Jiri, H. Martin, S. Petr,
- 520 9_
- $a The status of regional lymph nodes is the most important prognostic factor in early cervical cancer patients. Pelvic lymph node dissections are routinely performed as a part of standard surgical treatment. Systematic pelvic lymphadenectomy is associated with short- and long-term morbidities. This review discusses single components of the sentinel lymph node mapping (SLNM) technique and results of the detection of sentinel lymph nodes. SLNM biopsy performed by an experienced team for small volume tumors (<2 cm) has high specific side detection rate, excellent negative-predictive value and high sensitivity. Uncommon lymphatic drainage has been reported in 15% of cervical cancer patients. There is sufficient data now to suggest that SLNM with 99mTc plus blue dye in the hands of a surgeon with extensive experience should prove to be an important part of individualized cervical cancer surgery and increase the safety of less radical or fertility-sparing surgery.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfadenektomie $7 D008197
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a biopsie sentinelové lymfatické uzliny $x metody $7 D021701
- 650 _2
- $a technecium $x diagnostické užití $7 D013667
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a nádory děložního čípku $x patologie $x terapie $7 D002583
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Robová, Helena $u - $7 xx0110282
- 700 1_
- $a Halaška, Michael J., $u - $d 1975- $7 xx0062494
- 700 1_
- $a Hruda, Martin $u - $7 xx0239079
- 700 1_
- $a Škapa, Petr $u - $7 xx0105776
- 773 0_
- $w MED00174405 $t Expert review of anticancer therapy $x 1744-8328 $g Roč. 13, č. 7 (2013), s. 861-870
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23875664 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140401 $b ABA008
- 991 __
- $a 20181105140533 $b ABA008
- 999 __
- $a ok $b bmc $g 1018035 $s 849479
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 13 $c 7 $d 861-870 $i 1744-8328 $m Expert review of anticancer therapy $n Expert Rev Anticancer Ther $x MED00174405
- GRA __
- $a NT13166 $p MZ0
- LZP __
- $a Pubmed-20140401